FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight BY Dylan Berman • July 24, 2026July 24, 2026 Hims & Hers Health Inc. (NYSE:HIMS) is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pha[...] Read more